These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 22007077)

  • 1. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
    Shah Z; Kampfrath T; Deiuliis JA; Zhong J; Pineda C; Ying Z; Xu X; Lu B; Moffatt-Bruce S; Durairaj R; Sun Q; Mihai G; Maiseyeu A; Rajagopalan S
    Circulation; 2011 Nov; 124(21):2338-49. PubMed ID: 22007077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Ta NN; Schuyler CA; Li Y; Lopes-Virella MF; Huang Y
    J Cardiovasc Pharmacol; 2011 Aug; 58(2):157-66. PubMed ID: 21558879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-α Inhibition.
    Zhu L; Giunzioni I; Tavori H; Covarrubias R; Ding L; Zhang Y; Ormseth M; Major AS; Stafford JM; Linton MF; Fazio S
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1483-95. PubMed ID: 27365402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
    Yisireyili M; Takeshita K; Hayashi M; Wu H; Uchida Y; Yamamoto K; Kikuchi R; Hao CN; Nakayama T; Cheng XW; Matsushita T; Nakamura S; Murohara T
    Psychoneuroendocrinology; 2016 Nov; 73():186-195. PubMed ID: 27509090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.
    Akita K; Isoda K; Shimada K; Daida H
    J Am Heart Assoc; 2015 Mar; 4(3):e001469. PubMed ID: 25770025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.
    Hirano T; Mori Y
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):80-6. PubMed ID: 27186361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice.
    Kohashi K; Hiromura M; Mori Y; Terasaki M; Watanabe T; Kushima H; Shinmura K; Tomoyasu M; Nagashima M; Hirano T
    J Atheroscler Thromb; 2016; 23(4):441-54. PubMed ID: 26549734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
    Ervinna N; Mita T; Yasunari E; Azuma K; Tanaka R; Fujimura S; Sukmawati D; Nomiyama T; Kanazawa A; Kawamori R; Fujitani Y; Watada H
    Endocrinology; 2013 Mar; 154(3):1260-70. PubMed ID: 23337530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2017 Sep; 96-98():19-25. PubMed ID: 28347868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 fatty acids ameliorate atherosclerosis by favorably altering monocyte subsets and limiting monocyte recruitment to aortic lesions.
    Brown AL; Zhu X; Rong S; Shewale S; Seo J; Boudyguina E; Gebre AK; Alexander-Miller MA; Parks JS
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2122-30. PubMed ID: 22814747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
    Higashijima Y; Tanaka T; Yamaguchi J; Tanaka S; Nangaku M
    Am J Physiol Renal Physiol; 2015 Apr; 308(8):F878-87. PubMed ID: 25656369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-inflammatory vasostatin-2 attenuates atherosclerosis in ApoE
    Xiong W; Wang X; Dai D; Zhang B; Lu L; Tao R
    Thromb Haemost; 2017 Jan; 117(2):401-414. PubMed ID: 27831589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
    Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
    Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages.
    Brenner C; Franz WM; Kühlenthal S; Kuschnerus K; Remm F; Gross L; Theiss HD; Landmesser U; Kränkel N
    Int J Cardiol; 2015 Nov; 199():163-9. PubMed ID: 26197403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPK activation reduces the number of atheromata macrophages in ApoE deficient mice.
    Wang J; Ma A; Zhao M; Zhu H
    Atherosclerosis; 2017 Mar; 258():97-107. PubMed ID: 28235712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S; Nwosu AC; Mukherjee D; Hernandez GT
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
    Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.
    Uchida T; Oda T; Matsubara H; Watanabe A; Takechi H; Oshima N; Sakurai Y; Kumagai H
    Ren Fail; 2017 Nov; 39(1):340-349. PubMed ID: 28118775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
    Vittone F; Liberman A; Vasic D; Ostertag R; Esser M; Walcher D; Ludwig A; Marx N; Burgmaier M
    Diabetologia; 2012 Aug; 55(8):2267-75. PubMed ID: 22648661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmuscle myosin light-chain kinase deficiency attenuates atherosclerosis in apolipoprotein E-deficient mice via reduced endothelial barrier dysfunction and monocyte migration.
    Sun C; Wu MH; Yuan SY
    Circulation; 2011 Jul; 124(1):48-57. PubMed ID: 21670231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.